dibutyl (2R,3R)-2,3-diphosphonooxybutanedioate;N,N-diethylethanamine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: dibutyl (2R,3R)-2,3-diphosphonooxybutanedioate;N,N-diethylethanamine
• 化学式: C24H54N2O12P2
• 分子量: 624.6
• InChiKey: UEKXQHHSAXLLNS-HSTMFJOWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.33
• 重原子数：
  40
• 可旋转键数：
  21
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  193
• 氢给体数：
  4
• 氢受体数：
  14

文献信息

• PHOSPHORYLATED POLYOLS, PYROPHOSPHATES, AND DERIVATIVES THEREOF HAVING BIOLOGICAL ACTIVITY
  申请人：NormOxys, Inc.

  公开号：US20140142052A1

  公开（公告）日：2014-05-22

  The present invention provides phosphorylated and pyrophosphate derivatives of polyols, and structural derivatives of these compounds, and provides pharmaceutical compositions comprising the same. The compounds and compositions disclosed herein have various biological activities, including for example, as allosteric effectors of hemoglobin and/or as kinase inhibitors. The present invention further provides methods for therapy in human or mammalian patients, and methods for synthesis of biologically active compounds and their intermediates.

  本发明提供了聚醇的磷酸化和焦磷酸酯衍生物，以及这些化合物的结构衍生物，并提供包含它们的药物组合物。本文披露的化合物和组合物具有各种生物活性，例如作为血红蛋白的变构效应物或激酶抑制剂。本发明还提供了用于人类或哺乳动物患者治疗的方法，以及用于合成生物活性化合物及其中间体的方法。
• MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT
  申请人：NormOxys, Inc.

  公开号：EP2968617A1

  公开（公告）日：2016-01-20
• INOSITOL-BASED IMMUNOTHERAPIES
  申请人：NormOxys, Inc.

  公开号：EP3787634A1

  公开（公告）日：2021-03-10
• [EN] MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT<br/>[FR] UTILISATION DU MYO-INOSITOL TRISPYROPHOSPHATE COMME AGENT ANTI-OBÉSITÉ
  申请人：NORMOXYS INC

  公开号：WO2014143939A1

  公开（公告）日：2014-09-18

  The present invention provides for novel treatments of obesity and overweight and related disorders. The invention provides, in part, method of treatment comprising, or uses of inositol-tripyrophosphate (ITPP) in these disease states. Obesity refers to the medical condition in which adipose tissue (body fat) is systemically accumulated as a result of, for example, energy intake that is higher than energy expenditure over a long period of time. Obesity may result in various associated diseases, such as arteriosclerosis.
• [EN] MYO-INOSITOL TRISPYROPHOSHATE AS AN ANTI-DIABETIC AGENT<br/>[FR] TRISPYROPHOSHATE DE MYO-INOSITOL UTILE EN TANT QU'AGENT ANTI-DIABÉTIQUE
  申请人：NICOLAU YVES CLAUDE

  公开号：WO2015138916A1

  公开（公告）日：2015-09-17

  The present invention provides for novel treatments of diabetes, and related disorders. The invention provides, in part, method of treatment comprising, or uses of inositol-tripyrophosphate (ITPP) in these disease states. In some aspects, the present invention provides for methods of treatment comprising administering ITPP (and/or compounds related to ITPP) and/or uses of ITPP (and/or compounds related to ITPP) in the treatment of or manufacture of a medicament for treating diabetes, prediabetes, and/or glucose intolerance.